http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101468773-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2012-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101468773-B1 |
| titleOfInvention | Pharmaceutical Composition Comprising Histone H3K9 Methyltransferase G9a for Preventing and Treating Myeloproliferative Disorders |
| abstract | The present invention provides a pharmaceutical composition for preventing or treating a bone marrow proliferative disorder comprising a histone H3K9 methyltransferase G9a protein and a pharmaceutically acceptable carrier. The histone H3K9 methyltransferase G9a according to the present invention inhibits the transcription of JAK2 and inhibits the transcription of HLA-H3K9 methyltransferase gene, HLA-A, in the differentiation induction therapy using ATRA (all-trans retinoic acid, tretinoin) 60, and can be usefully used in the form of a cell therapy agent or a protein therapeutic agent for the treatment or prevention of a disease associated with JAK2 activity and mutation, specifically, a myeloproliferative disorder. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190031751-A |
| priorityDate | 2012-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 142.